Cargando…

Isolation of circulating tumor cells and detection of EGFR mutations in patients with non-small-cell lung cancer

The aim of the present study was to develop a procedure for the isolation of circulating tumor cells (CTCs), and to evaluate its application in the detection of epidermal growth factor receptor (EGFR) mutations, and potential heterogeneity in patients with non-small-cell lung cancer (NSCLC). Periphe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qi, Nong, Jingying, Wang, Jinghui, Yan, Zhuohong, Yi, Ling, Gao, Xin, Liu, Zhidong, Zhang, Hongtao, Zhang, Shucai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403494/ https://www.ncbi.nlm.nih.gov/pubmed/30881500 http://dx.doi.org/10.3892/ol.2019.10016

Ejemplares similares

A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer
por: Wang, Helin, et al.
Publicado: (2021)

CD137 ligand feedback upregulates PD‐L1 expression on lung cancer via T cell production of IFN‐γ
por: Wang, Helin, et al.
Publicado: (2019)

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
por: Nong, Jingying, et al.
Publicado: (2018)

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients
por: Zhang, Hui, et al.
Publicado: (2023)

Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
por: Nong, Jingying, et al.
Publicado: (2019)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
por: Xu, Jing, et al.
Publicado: (2017)

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
por: Li, Shih-Hong, et al.
Publicado: (2022)

Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
por: Nong, Jingying, et al.
Publicado: (2021)

Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non‐small‐cell lung cancer: Systematic review and meta analysis
por: Liu, Yinghui, et al.
Publicado: (2016)

Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma
por: Zhang, Quan, et al.
Publicado: (2015)

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer
por: Tong, Bing, et al.
Publicado: (2018)

Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
por: Qiao, Xiaojuan, et al.
Publicado: (2015)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
por: Zhao, Dan, et al.
Publicado: (2017)

Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients
por: Yu, Qian, et al.
Publicado: (2017)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
por: Ali, Azhar, et al.
Publicado: (2018)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang, Wenting, et al.
Publicado: (2018)

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
por: Liu, Yang, et al.
Publicado: (2017)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Prediction of EGFR Mutation Status in Non–Small Cell Lung Cancer Based on Ensemble Learning
por: Feng, Youdan, et al.
Publicado: (2022)

Detecting EGFR Mutations in Patients with Non-small Cell Lung Cancer
por: Hammoudeh, ZA, et al.
Publicado: (2018)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

How to Treat EGFR-Mutated Non–Small Cell Lung Cancer
por: Belani, Neel, et al.
Publicado: (2023)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
por: Wang, Fang, et al.
Publicado: (2019)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non-small cell lung cancer
por: Guan, Jian, et al.
Publicado: (2019)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients
por: Szpechcinski, Adam, et al.
Publicado: (2019)

Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation
por: Cho, Min-Sun, et al.
Publicado: (2020)

EGFR mutations subset in Chinese lung squamous cell carcinoma patients
por: Sun, Ying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ulsnli1gk0me4etejs15ks9qfe